参考文献/References:
[1] Orr GA, Verdier-Pinard P, McDaid H, et al. Mechanisms of Taxol resistance related to microtubules[J]. Oncogene, 2003,47(22):7280-7295.
[2] Kang SJ, Mintz GS, Park DW, et al. Mechanisms of in-stent restenosis after drug-eluting stent implantation: intravascular ultrasound analysis[J]. Circ Cardiovasc Interv,2011,4(1):9-14.
[3] Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions[J]. Circulation,2007,5(1):2344-2351.
[4] Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital(RESEARCH)study[J]. Circulation, 2004,109(11):1366-1370.
[5] Alfonso F, Pérez-Vizcayno MJ, Dutary J, et al. Implantation of a drug-eluting stent with a different drug(switch strategy)in patients with drug-eluting stent restenosis. Results from a prospective multicenter study(RIBS Ⅲ [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent])[J]. JACC Cardiovasc Interv,2012,5(7):728-737.
[6] Byrne RA, Neumann F, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent(ISAR-DESIRE 3): a randomised, open-label trial[J]. Lancet,2013,381(9865):461-467.
[7] 随永刚,滕思勇,裴汉军,等,药物洗脱支架内再狭窄再次置入支架的远期疗效和安全性[J].疑难病杂志,2014,6:555-557.
[8] Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al.Rationale and design of the RIBS Ⅳ randomised clinical trial(drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis)[J/OL]. EuroIntervention,2014, doi: 10.4244/EIJY14M09_07[Epub ahead of print].
[9] Kufner S, Byrne RA, de Waha A, et al. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial[J]. Cardiovasc Revasc Med,2014,15(2):69-75.
[10] Goldberg SL, Colombo A, Nakamura S, et al. Benefit of intracoronary ultrasound in the deployment of Palmaz-Schatz stents[J]. J Am Coll Cardiol,1994,24(4):996-1003.
[11] Hong MK, Mintz GS, Lee CW, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation[J]. Eur Heart J,2006,27(11):1305-1310.
[12] Zhang Y, Farooq V, Garcia-Garcia HM, et al. Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients[J]. EuroIntervention,2012,8:855-865.
[13] Kang SJ, Ahn JM, Song H, et al. Comprehensive intravascular ultrasound assessment of stent area and its impact on restenosis and adverse cardiac events in 403 patients with unprotected left main disease[J]. Circ Cardiovasc Interv,2011,4:562-569.
[14] Witzenbichler B, Maehara A, Weisz G, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents(ADAPTDES)study[J]. Circulation,2014,129:463-470.
[15] Brezinski ME, Tearney GJ, Bouma BE, et al.Imaging of coronary artery microstructure(in vitro)with optical coherence tomography[J]. Am J Cardiol,1996,77(1):92-93.
[16] Gonzalo N, Serruys PW, Okamura T, et al. Optical coherence tomography assessment of the acute effects of stent implantation on the vessel wall: a systematic quantitative approach[J]. Heart,2009,95(23):1913-1919.
[17] Terashima M, Rathore S, Suzuki Y, et al. Accuracy and reproducibility of stent-strut thickness determined by optical coherence tomography[J]. J Invasive Cardiol,2009,21(11):602-605.
[18] Matsumoto D, Shite J, Shinke T, et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography[J]. Eur Heart J,2007,28(8):961-967.
[19] 蒋晓栋,吴永健,俞梦越,等. 光学相干断层成像在经皮冠状动脉介入治疗前后的应用[J]. 中国循环杂志,2010,6:424-427.
[20] Magnus PC, Jayne JE, Garcia-Garcia HM, et al.Optical coherence tomography vs intravascular ultrasound in the evaluation of observer variability and reliability in the assessment of stent deployment: The OCTIVUS Study[J]. Catheter Cardiovasc Interv,2015,86(2):229-235.
[21] 乔树宾,戴军,胡奉环,等. 心血管介入治疗高级培训教程[M]. 北京:人民卫生出版社,2011:224-225.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(5):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[7]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(5):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]